•
Sep 30, 2020

OrthoPediatrics Q3 2020 Earnings Report

OrthoPediatrics demonstrated revenue growth and improved EBITDA, achieving positive adjusted EBITDA.

Key Takeaways

OrthoPediatrics Corp. reported a 7.0% increase in total revenue for Q3 2020, reaching $22.2 million, driven by a 16.7% growth in U.S. revenue. The company also achieved positive adjusted EBITDA, reflecting strong gross margin and cost control.

Total revenue increased by 7.0% to $22.2 million compared to Q3 2019.

U.S. revenue grew by 16.7% compared to the same period last year.

Adjusted EBITDA was positive during the quarter.

Orthex execution continued strongly, with a 167% increase in first-time users year-to-date.

Total Revenue
$22.2M
Previous year: $20.7M
+7.0%
EPS
-$0.24
Previous year: -$0.18
+33.3%
Gross Profit Margin
79.4%
Previous year: 76.6%
+3.7%
Gross Profit
$17.6M
Cash and Equivalents
$88.4M
Free Cash Flow
-$4.95M
Total Assets
$308M

OrthoPediatrics

OrthoPediatrics

OrthoPediatrics Revenue by Segment

OrthoPediatrics Revenue by Geographic Location

Forward Guidance

The Company expects overall sales growth during the fourth quarter 2020 to be similar to the third quarter. Fourth quarter sales growth in the U.S. is expected to accelerate slightly, while the international sales decline in the fourth quarter should be similar to the third quarter.

Revenue & Expenses

Visualization of income flow from segment revenue to net income